« Tel Aviv Neurotech Cluster Thrives |
Main
| The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics »
February 1, 2010
Neuropharma FDA Approvals Down in 2009
Posted by Zack Lynch
As we report today in this month's edition of Neurotech Insights, five of the 26 new drugs and biologics approved by the FDA were neuropharmaceuticals: Vanda/Novartis’ Fanapt for schizophrenia, Lundbeck's Sabril for infantile spasms and add-on for refractory partial seizures, Cypress/Forest’s Savella for fibromyalgia, Merck's (Organon) Saphris for bipolar and schizophrenia, and Novartis’ branded version of betaseron for multiple sclerosis.. This compares to seven neuropharmaceutical approvals out of 24 in 2008 (Pristiq, Relistor, Entereg, Xenazine, Vimpat, Banzel and tapentadol) and only two of 17 in 2007.
Comments (0)
+ TrackBacks (0) | Category: Neuropharma
POST A COMMENT
Thanks for signing in,
.
Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)
- RELATED ENTRIES
- › Neurotech 2010: Translational Researchers Highlight Innovation
- › The Neuro Revolution in China Progressing
- › Speakers for Neurotech 2010 - Boston, May 19-20
- › Giving the Brain a Voice: NIO Public Policy Tour in DC tomorrow
- › McGovern Institue for Brain Research at MIT Goes Web 2.0
- › The Neurodiagnostics Report 2010: Brain Imaging, Biomarkers and NeuroInformatics
- › Neuropharma FDA Approvals Down in 2009
- › Tel Aviv Neurotech Cluster Thrives
Zack Lynch is author of 
